Question
stringlengths 31
235
| Answer
stringlengths 1
1k
| Evidence Text
sequencelengths 1
4
| Company Name
stringclasses 48
values | Ticker
stringclasses 48
values | Filing year
float64 2.02k
2.02k
| Filing date
stringclasses 44
values | CIK
float64 2.49k
1.75M
| GICS_Sector
stringclasses 16
values | URL_HTML
stringclasses 51
values | q-id
int64 0
2.31k
| in-prod
float64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|
What is the balance of Exxon Mobil Corporation's Euro-denominated long-term debt maturing in FY 2028 at the end of FY 2023? | The balance at the end of FY 2023 of Exxon Mobil Corporation's Euro-denominated long-term debt that will mature in FY 2028 is $1,105 million. | [
"(millions of dollars, except where stated otherwise)\r\nAverage\r\nRate\r\nDec 31, 2023 Dec 31, 2022\r\nExxon Mobil Corporation\r\n3.176% notes due 2024 — 1,000\r\n2.019% notes due 2024 — 1,000\r\n2.709% notes due 2025 1,750 1,750\r\n2.992% notes due 2025 2,767 2,781\r\n3.043% notes due 2026 2,500 2,500\r\n2.275% notes due 2026 1,000 1,000\r\n3.294% notes due 2027 1,000 1,000\r\n2.440% notes due 2029 1,250 1,250\r\n3.482% notes due 2030 2,000 2,000\r\n2.610% notes due 2030 2,000 2,000\r\n2.995% notes due 2039 750 750\r\n4.227% notes due 2040 2,080 2,084\r\n3.567% notes due 2045 1,000 1,000\r\n4.114% notes due 2046 2,500 2,500\r\n3.095% notes due 2049 1,500 1,500\r\n4.327% notes due 2050 2,750 2,750\r\n3.452% notes due 2051 2,750 2,750\r\nExxon Mobil Corporation - Euro-denominated\r\n0.142% notes due 2024 — 1,600\r\n0.524% notes due 2028 1,105 1,066\r\n0.835% notes due 2032 1,105 1,066\r\n1.408% notes due 2039 1,105 1,066\r\nXTO Energy Inc.\r\n6.100% senior notes due 2036 189 189\r\n6.750% senior notes due 2037 286 289\r\n6.375% senior notes due 2038 223 224\r\nIndustrial revenue bonds due 2022-2051 3.080% 2,123 2,245\r\nFinance leases & other obligations 5.985% 3,838 3,299\r\nDebt issuance costs (88) (100)\r\nTotal long-term debt 37,483 40,559\r"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,949 | 0 |
What is the total accumulated pension benefit obligation for Exxon Mobil's U.S. operations at the close of FY 2023? | The total accumulated pension benefit obligation for Exxon Mobil's U.S. operations at the end of FY 2023 was $11,033 million. | [
"Pension Benefits Other Postretirement\r\nBenefits\r\n(millions of dollars, except where stated otherwise)\r\nU.S. Non-U.S.\r\n2023 2022 2023 2022 2023 2022\r\nWeighted-average assumptions used to determine\r\nbenefit obligations at December 31\r\nDiscount rate (percent) 5.30 5.60 4.30 4.90 5.30 5.60\r\nLong-term rate of compensation increase (percent) 4.50 4.50 4.50 5.20 4.50 4.50\r\nChange in benefit obligation\r\nBenefit obligation at January 1 12,350 18,511 19,342 29,492 5,211 7,265\r\nService cost 466 712 323 570 78 138\r\nInterest cost 664 518 922 614 276 216\r\nActuarial loss/(gain) 550 (4,432) 1,393 (7,742) 176 (1,990)\r\nBenefits paid (870) (2,959) (1,214) (1,415) (545) (492)\r\nForeign exchange rate changes — — 515 (2,258) 11 (47)\r\nAmendments, divestments and other (17) — 46 81 (193) 121\r\nBenefit obligation at December 31 13,143 12,350 21,327 19,342 5,014 5,211\r\nAccumulated benefit obligation at December 31 11,033 10,367 19,769 18,047 — —\r"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,950 | 0 |
How much did Exxon Mobil's non-U.S. operations contribute to the total capital and exploration expenditures in FY 2023 | n FY 2023, the total capital and exploration expenditures for non-U.S. operations amounted to $14,881 million out of a total of $26,325 million, indicating a significant contribution of 56.53% to Exxon Mobil's overall investment in capital and exploration activities. | [
"(millions of dollars)\r\n2023 2022\r\nU.S. Non-U.S. Total U.S. Non-U.S. Total\r\nUpstream (including exploration expenses) 8,813 10,948 19,761 6,968 10,034 17,002\r\nEnergy Products 1,195 1,580 2,775 1,351 1,059 2,410\r\nChemical Products 751 1,962 2,713 1,123 1,842 2,965\r\nSpecialty Products 63 391 454 46 222 268\r\nOther 622 — 622 59 — 59\r\nTotal 11,444 14,881 26,325 9,547 13,157 22,704"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,951 | 0 |
What was the amount of Exxon Mobil's cash and cash equivalents at the end of FY 2023? | Exxon Mobil had $31,539 million in cash and cash equivalents at the end of FY 2023. | [
"CONSOLIDATED BALANCE SHEET\r\n(millions of dollars)\r\nNote\r\nReference\r\nNumber\r\nDecember 31,\r\n2023\r\nDecember 31,\r\n2022\r\nASSETS\r\nCurrent assets\r\nCash and cash equivalents 31,539 29,640\r\nCash and cash equivalents – restricted 29 25\r\nNotes and accounts receivable – net\r\n6 38,015 41,749\r\nInventories\r\nCrude oil, products and merchandise\r\n3 20,528 20,434\r\nMaterials and supplies 4,592 4,001\r\nOther current assets 1,906 1,782\r\nTotal current assets 96,609 97,631"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,952 | 0 |
What is the value by which Exxon Mobils trade payables have increased or decreased in FY 2023? | Exxon Mobil's trade payables decreased by $1,920 million from $33,169 million at the end of FY 2022 to $31,249 million at the end of FY 2023. | [
"(millions of dollars) Dec 31, 2023 Dec 31, 2022\r\nNotes and accounts receivable\r\nTrade, less reserves of $170 million and $168 million 30,296 32,844\r\nOther, less reserves of $101 million and $402 million 7,719 8,905\r\nTotal 38,015 41,749\r\nNotes and loans payable\r\nBank loans 6 379\r\nCommercial paper 75 74\r\nLong-term debt due within one year 4,009 181\r\nTotal 4,090 634\r\nAccounts payable and accrued liabilities\r\nTrade payables 31,249 33,169\r\nPayables to equity companies 11,885 14,585\r\nAccrued taxes other than income taxes 3,817 3,969\r\nOther 11,086 11,474\r\nTotal 58,037 63,197"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,953 | 0 |
What is the value of long-term debt due within one year at the end of FY 2023 for Exxon Mobil? | The value of long-term debt due within one year at the end of FY 2023 for Exxon Mobil is $4,009 million. | [
"(millions of dollars) Dec 31, 2023 Dec 31, 2022\r\nNotes and accounts receivable\r\nTrade, less reserves of $170 million and $168 million 30,296 32,844\r\nOther, less reserves of $101 million and $402 million 7,719 8,905\r\nTotal 38,015 41,749\r\nNotes and loans payable\r\nBank loans 6 379\r\nCommercial paper 75 74\r\nLong-term debt due within one year 4,009 181\r\nTotal 4,090 634\r\nAccounts payable and accrued liabilities\r\nTrade payables 31,249 33,169\r\nPayables to equity companies 11,885 14,585\r\nAccrued taxes other than income taxes 3,817 3,969\r\nOther 11,086 11,474\r\nTotal 58,037 63,197"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,954 | 0 |
How did the net value of Property, Plant, and Equipment for Exxon Mobil's Chemical Products segment change from FY 2022 to FY 2023? | The net value of Property, Plant, and Equipment for Exxon Mobil's Chemical Products segment increased by 6.64% from FY 2022 to FY 2023. | [
"Property, Plant and Equipment\r\n(millions of dollars)\r\nDecember 31, 2023 December 31, 2022\r\nCost Net Cost Net\r\nUpstream 359,031 148,245 350,748 144,146\r\nEnergy Products 57,400 27,284 58,393 26,765\r\nChemical Products 38,801 20,329 36,322 19,064\r\nSpecialty Products 9,385 4,378 8,895 4,303\r\nOther 22,768 14,704 18,335 10,414\r\nTotal 487,385 214,940 472,693 204,692"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,955 | 0 |
Which segment of Exxon Mobil Corporation had the highest net value of Property, Plant, and Equipment as of the end of FY 2023? | The segment of Exxon Mobil Corporation with the highest net value of Property, Plant, and Equipment as of the end of FY 2023 was the Upstream segment, with a net value of $148,245 million. | [
"Property, Plant and Equipment\r\n(millions of dollars)\r\nDecember 31, 2023 December 31, 2022\r\nCost Net Cost Net\r\nUpstream 359,031 148,245 350,748 144,146\r\nEnergy Products 57,400 27,284 58,393 26,765\r\nChemical Products 38,801 20,329 36,322 19,064\r\nSpecialty Products 9,385 4,378 8,895 4,303\r\nOther 22,768 14,704 18,335 10,414\r\nTotal 487,385 214,940 472,693 204,692"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,956 | 0 |
How much did Exxon Mobil's right of use assets in operating leases increase from FY 2022 to FY 2023 in absolute terms? | The increase in Exxon Mobil's right of use assets in operating leases from FY 2022 to FY 2023 was $398 million. | [
"Balance Sheet\r\n(millions of dollars)\r\nOperating Leases Finance Leases\r\nDecember 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022\r\nRight of use assets\r\nIncluded in Other assets, including intangibles - net 6,849 6,451\r\nIncluded in Property, plant and equipment - net 2,712 2,090\r\nTotal right of use assets 6,849 6,451 2,712 2,090\r\nLease liability due within one year\r\nIncluded in Accounts payable and accrued liabilities 1,617 1,527 5 5\r\nIncluded in Notes and loans payable 95 69\r\nLong-term lease liability\r\nIncluded in Other long-term obligations 4,393 4,067\r\nIncluded in Long-term debt 1,821 1,389\r\nIncluded in Long-term obligations to equity\r\ncompanies 121 126\r\nTotal lease liability 6,010 5,594 2,042 1,589\r\nWeighted-average remaining lease term (years) 8 9 26 22\r\nWeighted-average discount rate (percent) 3.9 % 2.4 % 7.2 % 8.0 %\r"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,957 | 0 |
What was the amount of Interest expense in FY 2023 for Exxon Mobil? | The amount of interest expense for Exxon Mobil in FY 2023 was $849 million. | [
"CONSOLIDATED STATEMENT OF INCOME\r\n(millions of dollars)\r\nNote\r\nReference\r\nNumber\r\n2023 2022 2021\r\nRevenues and other income\r\nSales and other operating revenue\r\n18 334,697 398,675 276,692\r\nIncome from equity affiliates\r\n7 6,385 11,463 6,657\r\nOther income 3,500 3,542 2,291\r\nTotal revenues and other income 344,582 413,680 285,640\r\nCosts and other deductions\r\nCrude oil and product purchases 193,029 228,959 155,164\r\nProduction and manufacturing expenses 36,885 42,609 36,035\r\nSelling, general and administrative expenses 9,919 10,095 9,574\r\nDepreciation and depletion (includes impairments)\r\n2, 9 20,641 24,040 20,607\r\nExploration expenses, including dry holes 751 1,025 1,054\r\nNon-service pension and postretirement benefit expense\r\n17 714 482 786\r\nInterest expense 849 798 947\r\nOther taxes and duties\r\n19 29,011 27,919 30,239\r\nTotal costs and other deductions 291,799 335,927 254,406\r\nIncome (loss) before income taxes 52,783 77,753 31,234\r\nIncome tax expense (benefit)\r\n19 15,429 20,176 7,636\r\nNet income (loss) including noncontrolling interests 37,354 57,577 23,598\r\nNet income (loss) attributable to noncontrolling interests 1,344 1,837 558\r\nNet income (loss) attributable to ExxonMobil 36,010 55,740 23,040\r\nEarnings (loss) per common share (dollars)\r\n12 8.89 13.26 5.39\r\nEarnings (loss) per common share - assuming dilution (dollars) 12 8.89 13.26 5.39"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,958 | 0 |
How well did Exxon Mobil cover its interest expenses in FY 2023? | Exxon Mobil's interest coverage ratio in FY 2023 indicates that the company generated approximately 63.18 times more income than the amount needed to cover its interest expenses. | [
"CONSOLIDATED STATEMENT OF INCOME\r\n(millions of dollars)\r\nNote\r\nReference\r\nNumber\r\n2023 2022 2021\r\nRevenues and other income\r\nSales and other operating revenue\r\n18 334,697 398,675 276,692\r\nIncome from equity affiliates\r\n7 6,385 11,463 6,657\r\nOther income 3,500 3,542 2,291\r\nTotal revenues and other income 344,582 413,680 285,640\r\nCosts and other deductions\r\nCrude oil and product purchases 193,029 228,959 155,164\r\nProduction and manufacturing expenses 36,885 42,609 36,035\r\nSelling, general and administrative expenses 9,919 10,095 9,574\r\nDepreciation and depletion (includes impairments)\r\n2, 9 20,641 24,040 20,607\r\nExploration expenses, including dry holes 751 1,025 1,054\r\nNon-service pension and postretirement benefit expense\r\n17 714 482 786\r\nInterest expense 849 798 947\r\nOther taxes and duties\r\n19 29,011 27,919 30,239\r\nTotal costs and other deductions 291,799 335,927 254,406\r\nIncome (loss) before income taxes 52,783 77,753 31,234\r\nIncome tax expense (benefit)\r\n19 15,429 20,176 7,636\r\nNet income (loss) including noncontrolling interests 37,354 57,577 23,598\r\nNet income (loss) attributable to noncontrolling interests 1,344 1,837 558\r\nNet income (loss) attributable to ExxonMobil 36,010 55,740 23,040\r\nEarnings (loss) per common share (dollars)\r\n12 8.89 13.26 5.39\r\nEarnings (loss) per common share - assuming dilution (dollars) 12 8.89 13.26 5.39"
] | EXXON MOBIL CORP | XOM | 2,024 | 2024-02-28 | 34,088 | Energy | https://www.sec.gov/Archives/edgar/data/34088/000003408824000018/xom-20231231.htm | 1,959 | 0 |
What was Regeneron Pharmaceutical's total Revenues in FY 2023? | Regeneron Pharmaceutical's total Revenues in FY 2023 was $13,117 million. | [
"Year Ended December 31,\n (In millions, except per share data) 2023 2022 2021\n Revenues $ 13,117.2 $ 12,172.9 $ 16,071.7\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,061 | 0 |
Which product was the biggest contributor to Regeneron Pharmaceutical's total Revenues in FY 2023? | EYLEA - U.S was the biggest contributor to Regeneron Pharmaceutical's total Revenues in FY 2023 with a value of $5,719.6 million. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Net product sales:\n EYLEA HD - U.S. $ 165.8 $ — $ — $ 165.8 $ —\n EYLEA - U.S. 5,719.6 6,264.6 5,792.3 (545.0) 472.3\n Total EYLEA HD and EYLEA - U.S. 5,885.4 6,264.6 5,792.3 (379.2) 472.3\n Libtayo - U.S. 538.8 374.5 306.3 164.3 68.2\n Libtayo - ROW 324.3 73.0 — 251.3 73.0\n Total Libtayo - Global 863.1 447.5 306.3 415.6 141.2\n Praluent - U.S. 182.4 130.0 170.0 52.4 (40.0)\n REGEN-COV - U.S. — — 5,828.0 — (5,828.0)\n Evkeeza - U.S. 77.3 48.6 18.4 28.7 30.2\n Inmazeb - U.S. 69.8 3.0 — 66.8 3.0\n ARCALYST - U.S. — — 2.2 — (2.2)\n Total net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2 $ 184.3 $ (5,223.5)\n Collaboration revenue:\n Sanofi $ 3,799.5 $ 2,855.7 $ 1,902.2 $ 943.8 $ 953.5\n Bayer 1,487.5 1,430.7 1,409.3 56.8 21.4\n Roche 211.0 627.3 361.8 (416.3) 265.5\n Other 5.1 0.4 — 4.7 0.4\n Other revenue 536.1 365.1 281.2 171.0 83.9\n Total revenues $ 13,117.2 $ 12,172.9 $ 16,071.7 $ 944.3 $ (3,898.8)"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,062 | 0 |
What was the share of Total Net Product Sales in Regeneron Pharmaceutical's Total Revenues in FY 2023? | The Total Net Product Sales contributed 54% in Regeneron Pharmaceutical's Total Revenues in FY 2023. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Net product sales:\n EYLEA HD - U.S. $ 165.8 $ — $ — $ 165.8 $ —\n EYLEA - U.S. 5,719.6 6,264.6 5,792.3 (545.0) 472.3\n Total EYLEA HD and EYLEA - U.S. 5,885.4 6,264.6 5,792.3 (379.2) 472.3\n Libtayo - U.S. 538.8 374.5 306.3 164.3 68.2\n Libtayo - ROW 324.3 73.0 — 251.3 73.0\n Total Libtayo - Global 863.1 447.5 306.3 415.6 141.2\n Praluent - U.S. 182.4 130.0 170.0 52.4 (40.0)\n REGEN-COV - U.S. — — 5,828.0 — (5,828.0)\n Evkeeza - U.S. 77.3 48.6 18.4 28.7 30.2\n Inmazeb - U.S. 69.8 3.0 — 66.8 3.0\n ARCALYST - U.S. — — 2.2 — (2.2)\n Total net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2 $ 184.3 $ (5,223.5)\n Collaboration revenue:\n Sanofi $ 3,799.5 $ 2,855.7 $ 1,902.2 $ 943.8 $ 953.5\n Bayer 1,487.5 1,430.7 1,409.3 56.8 21.4\n Roche 211.0 627.3 361.8 (416.3) 265.5\n Other 5.1 0.4 — 4.7 0.4\n Other revenue 536.1 365.1 281.2 171.0 83.9\n Total revenues $ 13,117.2 $ 12,172.9 $ 16,071.7 $ 944.3 $ (3,898.8)"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,063 | 0 |
How much did Bayer Collaboration Revenue increase from FY 2022 to FY 2023 for Regeneron Pharmaceutical? | The Bayer Collaboration Revenue increased by 4% from FY 2022 to FY 2023 for Regeneron Pharmaceutical. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Net product sales:\n EYLEA HD - U.S. $ 165.8 $ — $ — $ 165.8 $ —\n EYLEA - U.S. 5,719.6 6,264.6 5,792.3 (545.0) 472.3\n Total EYLEA HD and EYLEA - U.S. 5,885.4 6,264.6 5,792.3 (379.2) 472.3\n Libtayo - U.S. 538.8 374.5 306.3 164.3 68.2\n Libtayo - ROW 324.3 73.0 — 251.3 73.0\n Total Libtayo - Global 863.1 447.5 306.3 415.6 141.2\n Praluent - U.S. 182.4 130.0 170.0 52.4 (40.0)\n REGEN-COV - U.S. — — 5,828.0 — (5,828.0)\n Evkeeza - U.S. 77.3 48.6 18.4 28.7 30.2\n Inmazeb - U.S. 69.8 3.0 — 66.8 3.0\n ARCALYST - U.S. — — 2.2 — (2.2)\n Total net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2 $ 184.3 $ (5,223.5)\n Collaboration revenue:\n Sanofi $ 3,799.5 $ 2,855.7 $ 1,902.2 $ 943.8 $ 953.5\n Bayer 1,487.5 1,430.7 1,409.3 56.8 21.4\n Roche 211.0 627.3 361.8 (416.3) 265.5\n Other 5.1 0.4 — 4.7 0.4\n Other revenue 536.1 365.1 281.2 171.0 83.9\n Total revenues $ 13,117.2 $ 12,172.9 $ 16,071.7 $ 944.3 $ (3,898.8)"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,064 | 0 |
What has been the growth of Total Net Product Sales for Regeneron Pharmaceutical in FY 2023 versus FY 2022? | The growth of Total Net Product Sales for Regeneron Pharmaceutical in FY 2023 versus FY 2022 was 2.7%. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Net product sales:\n EYLEA HD - U.S. $ 165.8 $ — $ — $ 165.8 $ —\n EYLEA - U.S. 5,719.6 6,264.6 5,792.3 (545.0) 472.3\n Total EYLEA HD and EYLEA - U.S. 5,885.4 6,264.6 5,792.3 (379.2) 472.3\n Libtayo - U.S. 538.8 374.5 306.3 164.3 68.2\n Libtayo - ROW 324.3 73.0 — 251.3 73.0\n Total Libtayo - Global 863.1 447.5 306.3 415.6 141.2\n Praluent - U.S. 182.4 130.0 170.0 52.4 (40.0)\n REGEN-COV - U.S. — — 5,828.0 — (5,828.0)\n Evkeeza - U.S. 77.3 48.6 18.4 28.7 30.2\n Inmazeb - U.S. 69.8 3.0 — 66.8 3.0\n ARCALYST - U.S. — — 2.2 — (2.2)\n Total net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2 $ 184.3 $ (5,223.5)\n Collaboration revenue:\n Sanofi $ 3,799.5 $ 2,855.7 $ 1,902.2 $ 943.8 $ 953.5\n Bayer 1,487.5 1,430.7 1,409.3 56.8 21.4\n Roche 211.0 627.3 361.8 (416.3) 265.5\n Other 5.1 0.4 — 4.7 0.4\n Other revenue 536.1 365.1 281.2 171.0 83.9\n Total revenues $ 13,117.2 $ 12,172.9 $ 16,071.7 $ 944.3 $ (3,898.8)"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,065 | 0 |
Which product was the lowest contributor to Regeneron Pharmaceutical's total Revenues in FY 2023? | Inmazeb - U.S. was the lowest contributor to Regeneron Pharmaceutical's total Revenues in FY 2023. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Net product sales:\n EYLEA HD - U.S. $ 165.8 $ — $ — $ 165.8 $ —\n EYLEA - U.S. 5,719.6 6,264.6 5,792.3 (545.0) 472.3\n Total EYLEA HD and EYLEA - U.S. 5,885.4 6,264.6 5,792.3 (379.2) 472.3\n Libtayo - U.S. 538.8 374.5 306.3 164.3 68.2\n Libtayo - ROW 324.3 73.0 — 251.3 73.0\n Total Libtayo - Global 863.1 447.5 306.3 415.6 141.2\n Praluent - U.S. 182.4 130.0 170.0 52.4 (40.0)\n REGEN-COV - U.S. — — 5,828.0 — (5,828.0)\n Evkeeza - U.S. 77.3 48.6 18.4 28.7 30.2\n Inmazeb - U.S. 69.8 3.0 — 66.8 3.0\n ARCALYST - U.S. — — 2.2 — (2.2)\n Total net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2 $ 184.3 $ (5,223.5)\n Collaboration revenue:\n Sanofi $ 3,799.5 $ 2,855.7 $ 1,902.2 $ 943.8 $ 953.5\n Bayer 1,487.5 1,430.7 1,409.3 56.8 21.4\n Roche 211.0 627.3 361.8 (416.3) 265.5\n Other 5.1 0.4 — 4.7 0.4\n Other revenue 536.1 365.1 281.2 171.0 83.9\n Total revenues $ 13,117.2 $ 12,172.9 $ 16,071.7 $ 944.3 $ (3,898.8)"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,066 | 0 |
What was the growth of Sanofi Collaboration Revenue in FY 2023 versus FY 2022 for Regeneron Pharmaceutical? | The growth of Sanofi Collaboration Revenue in FY 2023 versus FY 2022 for Regeneron Pharmaceutical was 33%. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Net product sales:\n EYLEA HD - U.S. $ 165.8 $ — $ — $ 165.8 $ —\n EYLEA - U.S. 5,719.6 6,264.6 5,792.3 (545.0) 472.3\n Total EYLEA HD and EYLEA - U.S. 5,885.4 6,264.6 5,792.3 (379.2) 472.3\n Libtayo - U.S. 538.8 374.5 306.3 164.3 68.2\n Libtayo - ROW 324.3 73.0 — 251.3 73.0\n Total Libtayo - Global 863.1 447.5 306.3 415.6 141.2\n Praluent - U.S. 182.4 130.0 170.0 52.4 (40.0)\n REGEN-COV - U.S. — — 5,828.0 — (5,828.0)\n Evkeeza - U.S. 77.3 48.6 18.4 28.7 30.2\n Inmazeb - U.S. 69.8 3.0 — 66.8 3.0\n ARCALYST - U.S. — — 2.2 — (2.2)\n Total net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2 $ 184.3 $ (5,223.5)\n Collaboration revenue:\n Sanofi $ 3,799.5 $ 2,855.7 $ 1,902.2 $ 943.8 $ 953.5\n Bayer 1,487.5 1,430.7 1,409.3 56.8 21.4\n Roche 211.0 627.3 361.8 (416.3) 265.5\n Other 5.1 0.4 — 4.7 0.4\n Other revenue 536.1 365.1 281.2 171.0 83.9\n Total revenues $ 13,117.2 $ 12,172.9 $ 16,071.7 $ 944.3 $ (3,898.8)"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,067 | 0 |
Did the Revenues of Praluent of Regeneron Pharmaceutical grow in FY 2023 versus FY 2022 in United States? | Yes, the Revenues of Praluent in United States for Regeneron Pharmaceutical did grow from $130 million in FY 2022 to $182.4 million in FY 2023. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Net product sales:\n EYLEA HD - U.S. $ 165.8 $ — $ — $ 165.8 $ —\n EYLEA - U.S. 5,719.6 6,264.6 5,792.3 (545.0) 472.3\n Total EYLEA HD and EYLEA - U.S. 5,885.4 6,264.6 5,792.3 (379.2) 472.3\n Libtayo - U.S. 538.8 374.5 306.3 164.3 68.2\n Libtayo - ROW 324.3 73.0 — 251.3 73.0\n Total Libtayo - Global 863.1 447.5 306.3 415.6 141.2\n Praluent - U.S. 182.4 130.0 170.0 52.4 (40.0)\n REGEN-COV - U.S. — — 5,828.0 — (5,828.0)\n Evkeeza - U.S. 77.3 48.6 18.4 28.7 30.2\n Inmazeb - U.S. 69.8 3.0 — 66.8 3.0\n ARCALYST - U.S. — — 2.2 — (2.2)\n Total net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2 $ 184.3 $ (5,223.5)\n Collaboration revenue:\n Sanofi $ 3,799.5 $ 2,855.7 $ 1,902.2 $ 943.8 $ 953.5\n Bayer 1,487.5 1,430.7 1,409.3 56.8 21.4\n Roche 211.0 627.3 361.8 (416.3) 265.5\n Other 5.1 0.4 — 4.7 0.4\n Other revenue 536.1 365.1 281.2 171.0 83.9\n Total revenues $ 13,117.2 $ 12,172.9 $ 16,071.7 $ 944.3 $ (3,898.8)"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,068 | 0 |
With which company did Regeneron Pharmaceutical generate the highest collaboration revenue in FY 2023? | Regeneron Pharmaceutical generated the highest collaboration revenue in FY 2023 with Sanofi with a total amount of $3,799.5 million. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Net product sales:\n EYLEA HD - U.S. $ 165.8 $ — $ — $ 165.8 $ —\n EYLEA - U.S. 5,719.6 6,264.6 5,792.3 (545.0) 472.3\n Total EYLEA HD and EYLEA - U.S. 5,885.4 6,264.6 5,792.3 (379.2) 472.3\n Libtayo - U.S. 538.8 374.5 306.3 164.3 68.2\n Libtayo - ROW 324.3 73.0 — 251.3 73.0\n Total Libtayo - Global 863.1 447.5 306.3 415.6 141.2\n Praluent - U.S. 182.4 130.0 170.0 52.4 (40.0)\n REGEN-COV - U.S. — — 5,828.0 — (5,828.0)\n Evkeeza - U.S. 77.3 48.6 18.4 28.7 30.2\n Inmazeb - U.S. 69.8 3.0 — 66.8 3.0\n ARCALYST - U.S. — — 2.2 — (2.2)\n Total net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2 $ 184.3 $ (5,223.5)\n Collaboration revenue:\n Sanofi $ 3,799.5 $ 2,855.7 $ 1,902.2 $ 943.8 $ 953.5\n Bayer 1,487.5 1,430.7 1,409.3 56.8 21.4\n Roche 211.0 627.3 361.8 (416.3) 265.5\n Other 5.1 0.4 — 4.7 0.4\n Other revenue 536.1 365.1 281.2 171.0 83.9\n Total revenues $ 13,117.2 $ 12,172.9 $ 16,071.7 $ 944.3 $ (3,898.8)"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,069 | 0 |
Regeneron Pharmaceutical generated the lowest collaboration revenue with which company in FY 2023? | Regeneron Pharmaceutical generated the lowest collaboration revenue in FY 2023 with Roche with a total amount of $211 million. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Net product sales:\n EYLEA HD - U.S. $ 165.8 $ — $ — $ 165.8 $ —\n EYLEA - U.S. 5,719.6 6,264.6 5,792.3 (545.0) 472.3\n Total EYLEA HD and EYLEA - U.S. 5,885.4 6,264.6 5,792.3 (379.2) 472.3\n Libtayo - U.S. 538.8 374.5 306.3 164.3 68.2\n Libtayo - ROW 324.3 73.0 — 251.3 73.0\n Total Libtayo - Global 863.1 447.5 306.3 415.6 141.2\n Praluent - U.S. 182.4 130.0 170.0 52.4 (40.0)\n REGEN-COV - U.S. — — 5,828.0 — (5,828.0)\n Evkeeza - U.S. 77.3 48.6 18.4 28.7 30.2\n Inmazeb - U.S. 69.8 3.0 — 66.8 3.0\n ARCALYST - U.S. — — 2.2 — (2.2)\n Total net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2 $ 184.3 $ (5,223.5)\n Collaboration revenue:\n Sanofi $ 3,799.5 $ 2,855.7 $ 1,902.2 $ 943.8 $ 953.5\n Bayer 1,487.5 1,430.7 1,409.3 56.8 21.4\n Roche 211.0 627.3 361.8 (416.3) 265.5\n Other 5.1 0.4 — 4.7 0.4\n Other revenue 536.1 365.1 281.2 171.0 83.9\n Total revenues $ 13,117.2 $ 12,172.9 $ 16,071.7 $ 944.3 $ (3,898.8)"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,070 | 0 |
What was Regeneron Pharmaceutical's total Income from Operations in FY 2023? | Regeneron Pharmaceutical's total income from operations in FY 2023 was $4,047 million. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,071 | 0 |
What was the Operating Margin of Regeneron Pharmaceutical in FY 2023? | The Operating Margin of Regeneron Pharmaceutical in FY 2023 was 30.8%. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,072 | 0 |
What was the growth in Regeneron Pharmaceutical's total income from operations in FY 2023 versus FY 2022? | Regeneron Pharmaceutical's Income from Operations decreased by 14.6% from FY 2022 to FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,073 | 0 |
How did the operating margin of Regeneron Pharmaceutical change from FY 2022 to FY 2023? | Regeneron Pharmaceutical's Operating Margin lowered from 38.9% in FY 2022 to 30.8% in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,074 | 0 |
What was the Cost of Goods Sold for Regeneron Pharmaceutical in FY 2023? | The Cost of Goods Sold for Regeneron Pharmaceutical in FY 2023 was $932.1 million. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,075 | 0 |
What was the Selling, general and administrative expense for Regeneron Pharmaceutical in FY 2023? | The Selling, General and Administrative expense for Regeneron Pharmaceutical in FY 2023 was $2,631.3 million. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,076 | 0 |
What proportion of Regeneron Pharmaceutical's Total Revenue was the Selling, general and administrative expense for FY 2023? | The Selling, general and administrative expense was 20.1% of Regeneron Pharmaceutical's Total Revenue in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,077 | 0 |
What was the growth in Regeneron Pharmaceutical's Selling, general and administrative expense in FY 2023 versus FY 2022? | The growth in Selling, general and administrative expense for Regeneron Pharmaceutical in FY 2023 was 24.4% versus FY 2022. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,078 | 0 |
Did the Net Income of Regeneron Pharmaceutical increase in FY 2023 versus FY 2022? | No, the Net Income of Regeneron Pharmaceutical decreased from $4,338.4 million in FY 2022 to $3,953.6 million in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,079 | 0 |
What proportion of Regeneron Pharmaceutical's Total Revenue was the Research and Development expense for FY 2023? | The Research and Development expense was 33.8% of Regeneron Pharmaceutical's Total Revenue in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,080 | 0 |
Did the Interest Expense increase from FY 2022 to FY 2023 for Regeneron Pharmaceutical? | Yes, the Interest Expense increased from $59.4 million in FY 2022 to $73 million in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,081 | 0 |
What was Regeneron Pharmaceutical's Basic Net Income per Share in FY 2023? | Regeneron Pharmaceutical's Basic Net Income per share in FY 2023 was $37.05. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,082 | 0 |
What has been the growth in Regeneron Pharmaceutical's basic net income per share from FY 2022 to FY 2023? | Regeneron Pharmaceutical's basic net income per share decreased by 8.5% from FY 2022 to FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,083 | 0 |
What was Regeneron Pharmaceutical's Diluted net income per share in FY 2023? | Regeneron Pharmaceutical's Dilued net income per share in FY 2023 was $34.77. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME\n (In millions, except per share data)\n Year Ended December 31,\n 2023 2022 2021\n Statements of Operations\n Revenues:\n Net product sales $ 7,078.0 $ 6,893.7 $ 12,117.2\n Collaboration revenue 5,503.1 4,914.1 3,673.3\n Other revenue 536.1 365.1 281.2\n 13,117.2 12,172.9 16,071.7\n Expenses:\n Research and development 4,439.0 3,592.5 2,860.1\n Acquired in-process research and development 186.1 255.1 48.0\n Selling, general, and administrative 2,631.3 2,115.9 1,824.9\n Cost of goods sold 932.1 800.0 1,773.1\n Cost of collaboration and contract manufacturing 883.7 760.4 664.4\n Other operating (income) expense, net (2.1) (89.9) (45.6)\n 9,070.1 7,434.0 7,124.9\n Income from operations 4,047.1 4,738.9 8,946.8\n Other income (expense):\n Other income (expense), net 225.2 179.3 436.3\n Interest expense (73.0) (59.4) (57.3)\n 152.2 119.9 379.0\n Income before income taxes 4,199.3 4,858.8 9,325.8\n Income tax expense 245.7 520.4 1,250.5\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Net income per share - basic $ 37.05 $ 40.51 $ 76.40\n Net income per share - diluted $ 34.77 $ 38.22 $ 71.97\n Weighted average shares outstanding - basic 106.7 107.1 105.7\n Weighted average shares outstanding - diluted 113.7 113.5 112.2\n Statements of Comprehensive Income\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Other comprehensive income (loss), net of tax:\n Unrealized gain (loss) on debt securities 158.2 (213.6) (56.4)\n Loss on foreign currency translation (0.3) — —\n Unrealized gain on cash flow hedges — 1.0 0.9\n Comprehensive income $ 4,111.5 $ 4,125.8 $ 8,019.8"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,084 | 0 |
What was the Operating Lease cost for Regeneron Pharmaceutical in FY 2023? | The Operating Lease cost for Regeneron Pharmaceutical in FY 2023 was $19.2 million. | [
"Year Ended December 31,\n (In millions) 2023 2022 2021\n Operating lease costs $ 19.2 $ 12.4 $ 10.3\n Finance lease costs:\n Amortization of finance lease right-of-use assets 14.5 14.5 14.4\n Interest on finance lease liabilities 45.0 21.6 11.9\n Total finance lease costs 59.5 36.1 26.3\n Total lease costs $ 78.7 $ 48.5 $ 36.6"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,085 | 0 |
What was the change in Operating Lease Cost for Regeneron Pharmaceutical from FY 2022 to FY 2023? | The Total Operating Lease Cost for Regeneron Pharmaceutical grew by 54.8% in FY 2023 versus FY 2022. | [
"Year Ended December 31,\n (In millions) 2023 2022 2021\n Operating lease costs $ 19.2 $ 12.4 $ 10.3\n Finance lease costs:\n Amortization of finance lease right-of-use assets 14.5 14.5 14.4\n Interest on finance lease liabilities 45.0 21.6 11.9\n Total finance lease costs 59.5 36.1 26.3\n Total lease costs $ 78.7 $ 48.5 $ 36.6"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,086 | 0 |
What was the effective income tax rate for Regeneron Pharmaceutical in FY 2023? | The effective income tax rate for Regeneron Pharmaceutical in FY 2023 was 5.9%. | [
"Year Ended December 31,\n 2023 2022 2021\n U.S. federal statutory tax rate 21.0 % 21.0 % 21.0 %\n Taxation of non-U.S. operations (6.6) (5.5) (2.8)\n Stock-based compensation (4.6) (2.9) (2.4)\n Income tax credits (3.2) (2.0) (1.0)\n Foreign-derived intangible income deduction (0.3) (1.0) (1.4)\n Other permanent differences (0.4) 1.1 —\n Effective income tax rate 5.9 % 10.7 % 13.4 %"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,087 | 0 |
How has Regeneron Pharmaceutical's effective income tax rate changed from FY 2022 to FY 2023? | Regeneron Pharmaceutical's effective income tax rate lowered from 10.7% in FY 2022 to 5.9% in FY 2023. | [
"Year Ended December 31,\n 2023 2022 2021\n U.S. federal statutory tax rate 21.0 % 21.0 % 21.0 %\n Taxation of non-U.S. operations (6.6) (5.5) (2.8)\n Stock-based compensation (4.6) (2.9) (2.4)\n Income tax credits (3.2) (2.0) (1.0)\n Foreign-derived intangible income deduction (0.3) (1.0) (1.4)\n Other permanent differences (0.4) 1.1 —\n Effective income tax rate 5.9 % 10.7 % 13.4 %"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,088 | 0 |
What was the total Deferred Tax Asset for Regeneron Pharmaceutical in FY 2023? | The total Deferred Tax Asset for Regeneron Pharmaceutical in FY 2023 was $2,625.8 million. | [
"As of December 31,\n (In millions) 2023 2022\n Deferred tax assets:\n Capitalized research and development expenses $ 1,728.2 $ 845.3\n Deferred compensation 413.6 416.2\n Accrued expenses 214.1 235.6\n Fixed assets and intangible assets 154.8 227.6\n Tax attribute carryforwards 88.7 41.3\n Other 26.4 15.9\n Total deferred tax assets 2,625.8 1,781.9\n Deferred tax liabilities:\n Unrealized gains on investments (50.4) (58.2)\n Net deferred tax assets $ 2,575.4 $ 1,723.7"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,089 | 0 |
Did the Total Deferred Tax Asset increase from FY 2022 to FY 2023? | Yes, the Total Deferred Tax Asset increased from $1,781.9 million in FY 2022 to $2,625.8 million in FY 2023. | [
"As of December 31,\n (In millions) 2023 2022\n Deferred tax assets:\n Capitalized research and development expenses $ 1,728.2 $ 845.3\n Deferred compensation 413.6 416.2\n Accrued expenses 214.1 235.6\n Fixed assets and intangible assets 154.8 227.6\n Tax attribute carryforwards 88.7 41.3\n Other 26.4 15.9\n Total deferred tax assets 2,625.8 1,781.9\n Deferred tax liabilities:\n Unrealized gains on investments (50.4) (58.2)\n Net deferred tax assets $ 2,575.4 $ 1,723.7"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,090 | 0 |
What was the total Research and Development expenses for Regeneron Pharmaceutical end of FY 2023? | the total Research and Development expenses for Regeneron Pharmaceutical end of FY 2023 was $4,439 million. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Direct research and development expenses:\n Dupixent (dupilumab) $ 168.0 $ 156.5 $ 146.4 $ 11.5 $ 10.1\n Fianlimab 112.2 43.4 8.7 68.8 34.7\n Libtayo (cemiplimab) 105.3 138.0 146.2 (32.7) (8.2)\n Odronextamab 96.3 66.0 34.9 30.3 31.1\n EYLEA HD (aflibercept) 8 mg 96.2 67.9 73.5 28.3 (5.6)\n Linvoseltamab 78.7 45.5 18.7 33.2 26.8\n Itepekimab 70.3 26.5 — 43.8 26.5\n Pozelimab 60.2 72.4 28.3 (12.2) 44.1\n REGEN-COV (5.6) 32.8 309.8 (38.4) (277.0)\n Other product candidates in clinical development and\n other research programs 514.0 393.9 429.7 120.1 (35.8)\n Total direct research and development expenses 1,295.6 1,042.9 1,196.2 252.7 (153.3)\n Indirect research and development expenses:\n Payroll and benefits 1,537.0 1,195.5 981.4 341.5 214.1\n Lab supplies and other research and development costs 210.6 181.0 142.0 29.6 39.0\n Occupancy and other operating costs 518.2 508.5 414.9 9.7 93.6\n Total indirect research and development expenses 2,265.8 1,885.0 1,538.3 380.8 346.7\n Clinical manufacturing costs 1,053.9 938.3 621.7 115.6 316.6\n Reimbursement of research and development expenses by\n collaborators (176.3) (273.7) (496.1) 97.4 222.4\n Total research and development expenses $ 4,439.0 $ 3,592.5 $ 2,860.1 $ 846.5 $ 732.4"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,091 | 0 |
How much did the total Research and Development expenses for Regeneron Pharmaceutical increase from FY 2022 to FY 2023? | The total Research and Development expenses for Regeneron Pharmaceutical increased from $3,592.5 million in FY 2022 to $4,439 million in FY 2023. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Direct research and development expenses:\n Dupixent (dupilumab) $ 168.0 $ 156.5 $ 146.4 $ 11.5 $ 10.1\n Fianlimab 112.2 43.4 8.7 68.8 34.7\n Libtayo (cemiplimab) 105.3 138.0 146.2 (32.7) (8.2)\n Odronextamab 96.3 66.0 34.9 30.3 31.1\n EYLEA HD (aflibercept) 8 mg 96.2 67.9 73.5 28.3 (5.6)\n Linvoseltamab 78.7 45.5 18.7 33.2 26.8\n Itepekimab 70.3 26.5 — 43.8 26.5\n Pozelimab 60.2 72.4 28.3 (12.2) 44.1\n REGEN-COV (5.6) 32.8 309.8 (38.4) (277.0)\n Other product candidates in clinical development and\n other research programs 514.0 393.9 429.7 120.1 (35.8)\n Total direct research and development expenses 1,295.6 1,042.9 1,196.2 252.7 (153.3)\n Indirect research and development expenses:\n Payroll and benefits 1,537.0 1,195.5 981.4 341.5 214.1\n Lab supplies and other research and development costs 210.6 181.0 142.0 29.6 39.0\n Occupancy and other operating costs 518.2 508.5 414.9 9.7 93.6\n Total indirect research and development expenses 2,265.8 1,885.0 1,538.3 380.8 346.7\n Clinical manufacturing costs 1,053.9 938.3 621.7 115.6 316.6\n Reimbursement of research and development expenses by\n collaborators (176.3) (273.7) (496.1) 97.4 222.4\n Total research and development expenses $ 4,439.0 $ 3,592.5 $ 2,860.1 $ 846.5 $ 732.4"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,092 | 0 |
Which product contributed the most to the Total Research and Development expenses of Regeneron Pharmaceutical in FY 2023? | Dupixent (dupilumab) contributed the most with an amount of $168 million to the Total Research and Development expenses of Regeneron Pharmaceutical in FY 2023. | [
"Year Ended December 31, $ Change\n (In millions) 2023 2022 2021 2023 vs. 2022 2022 vs. 2021\n Direct research and development expenses:\n Dupixent (dupilumab) $ 168.0 $ 156.5 $ 146.4 $ 11.5 $ 10.1\n Fianlimab 112.2 43.4 8.7 68.8 34.7\n Libtayo (cemiplimab) 105.3 138.0 146.2 (32.7) (8.2)\n Odronextamab 96.3 66.0 34.9 30.3 31.1\n EYLEA HD (aflibercept) 8 mg 96.2 67.9 73.5 28.3 (5.6)\n Linvoseltamab 78.7 45.5 18.7 33.2 26.8\n Itepekimab 70.3 26.5 — 43.8 26.5\n Pozelimab 60.2 72.4 28.3 (12.2) 44.1\n REGEN-COV (5.6) 32.8 309.8 (38.4) (277.0)\n Other product candidates in clinical development and\n other research programs 514.0 393.9 429.7 120.1 (35.8)\n Total direct research and development expenses 1,295.6 1,042.9 1,196.2 252.7 (153.3)\n Indirect research and development expenses:\n Payroll and benefits 1,537.0 1,195.5 981.4 341.5 214.1\n Lab supplies and other research and development costs 210.6 181.0 142.0 29.6 39.0\n Occupancy and other operating costs 518.2 508.5 414.9 9.7 93.6\n Total indirect research and development expenses 2,265.8 1,885.0 1,538.3 380.8 346.7\n Clinical manufacturing costs 1,053.9 938.3 621.7 115.6 316.6\n Reimbursement of research and development expenses by\n collaborators (176.3) (273.7) (496.1) 97.4 222.4\n Total research and development expenses $ 4,439.0 $ 3,592.5 $ 2,860.1 $ 846.5 $ 732.4"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,093 | 0 |
How much cash and cash equivalents did Regeneron Pharmaceutical hold end of FY 2023? | Regeneron Pharmaceutical held Cash and cash equivalents of $2,730 million by end of FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,094 | 0 |
How much net cash did Regeneron Pharmaceutical's operating activities generate in FY 2023? | Regeneron Pharmaceutical's operating activities generated net cash of $4,594 million in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF CASH FLOWS\n (In millions)\n Year Ended December 31,\n 2023 2022 2021\n Cash flows from operating activities:\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Adjustments to reconcile net income to net cash provided by operating activities:\n Depreciation and amortization 421.0 341.4 286.2\n Stock-based compensation expense 885.0 725.0 601.7\n Losses (gains) on marketable and other securities, net 266.4 36.8 (387.0)\n Other non-cash items, net (0.1) 368.0 568.7\n Deferred income taxes (837.8) (746.4) (147.1)\n Acquired in-process research and development in connection with asset acquisition — 195.0 —\n Changes in assets and liabilities:\n (Increase) decrease in accounts receivable (338.8) 707.8 (1,927.4)\n Increase in inventories (271.7) (696.5) (494.3)\n Increase in prepaid expenses and other assets (120.1) (148.6) (240.7)\n Increase (decrease) in deferred revenue 37.9 32.4 (120.2)\n Increase (decrease) in accounts payable, accrued expenses, and other liabilities 598.6 (138.4) 866.1\n Total adjustments 640.4 676.5 (994.0)\n Net cash provided by operating activities 4,594.0 5,014.9 7,081.3\n Cash flows from investing activities:\n Purchases of marketable and other securities (11,646.0) (7,487.9) (7,048.1)\n Sales or maturities of marketable and other securities 9,442.2 5,550.5 2,215.3\n Capital expenditures (718.6) (590.1) (551.9)\n Payments for Libtayo intangible asset (207.8) (1,026.8) —\n Acquisitions, net of cash acquired (54.9) (230.3) —\n Net cash used in investing activities (3,185.1) (3,784.6) (5,384.7)\n Cash flows from financing activities:\n Proceeds from issuance of Common Stock 1,145.5 1,519.5 1,672.3\n Payments in connection with Common Stock tendered for employee tax obligations (700.6) (445.7) (1,032.7)\n Repurchases of Common Stock (2,235.0) (2,082.8) (1,645.4)\n Net cash used in financing activities (1,790.1) (1,009.0) (1,005.8)\n Effect of exchange rate changes on cash, cash equivalents, and restricted cash (0.4) — —\n Net (decrease) increase in cash, cash equivalents, and restricted cash (381.6) 221.3 690.8\n Cash, cash equivalents, and restricted cash at beginning of period 3,119.4 2,898.1 2,207.3\n Cash, cash equivalents, and restricted cash at end of period $ 2,737.8 $ 3,119.4 $ 2,898.1\n Supplemental disclosure of cash flow information\n Cash paid for interest (net of amounts capitalized) $ 73.1 $ 53.7 $ 55.8\n Cash paid for income taxes $ 870.3 $ 1,502.4 $ 1,218.4"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,095 | 0 |
How much net cash did Regeneron Pharmaceutical use in investing activities in FY 2023? | Regeneron Pharmaceutical used $3,185 million in investing activities in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF CASH FLOWS\n (In millions)\n Year Ended December 31,\n 2023 2022 2021\n Cash flows from operating activities:\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Adjustments to reconcile net income to net cash provided by operating activities:\n Depreciation and amortization 421.0 341.4 286.2\n Stock-based compensation expense 885.0 725.0 601.7\n Losses (gains) on marketable and other securities, net 266.4 36.8 (387.0)\n Other non-cash items, net (0.1) 368.0 568.7\n Deferred income taxes (837.8) (746.4) (147.1)\n Acquired in-process research and development in connection with asset acquisition — 195.0 —\n Changes in assets and liabilities:\n (Increase) decrease in accounts receivable (338.8) 707.8 (1,927.4)\n Increase in inventories (271.7) (696.5) (494.3)\n Increase in prepaid expenses and other assets (120.1) (148.6) (240.7)\n Increase (decrease) in deferred revenue 37.9 32.4 (120.2)\n Increase (decrease) in accounts payable, accrued expenses, and other liabilities 598.6 (138.4) 866.1\n Total adjustments 640.4 676.5 (994.0)\n Net cash provided by operating activities 4,594.0 5,014.9 7,081.3\n Cash flows from investing activities:\n Purchases of marketable and other securities (11,646.0) (7,487.9) (7,048.1)\n Sales or maturities of marketable and other securities 9,442.2 5,550.5 2,215.3\n Capital expenditures (718.6) (590.1) (551.9)\n Payments for Libtayo intangible asset (207.8) (1,026.8) —\n Acquisitions, net of cash acquired (54.9) (230.3) —\n Net cash used in investing activities (3,185.1) (3,784.6) (5,384.7)\n Cash flows from financing activities:\n Proceeds from issuance of Common Stock 1,145.5 1,519.5 1,672.3\n Payments in connection with Common Stock tendered for employee tax obligations (700.6) (445.7) (1,032.7)\n Repurchases of Common Stock (2,235.0) (2,082.8) (1,645.4)\n Net cash used in financing activities (1,790.1) (1,009.0) (1,005.8)\n Effect of exchange rate changes on cash, cash equivalents, and restricted cash (0.4) — —\n Net (decrease) increase in cash, cash equivalents, and restricted cash (381.6) 221.3 690.8\n Cash, cash equivalents, and restricted cash at beginning of period 3,119.4 2,898.1 2,207.3\n Cash, cash equivalents, and restricted cash at end of period $ 2,737.8 $ 3,119.4 $ 2,898.1\n Supplemental disclosure of cash flow information\n Cash paid for interest (net of amounts capitalized) $ 73.1 $ 53.7 $ 55.8\n Cash paid for income taxes $ 870.3 $ 1,502.4 $ 1,218.4"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,096 | 0 |
What was Regeneron Pharmaceutical's working capital end of FY 2023? | Regeneron Pharmaceutical's working capital end of FY 2023 was $16,055.8 million. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,097 | 0 |
What was the change in Regeneron Pharmaceutical's working capital from FY 2022 to 2022? | Regeneron Pharmaceutical's working capital increased by $3,313 million from FY 2022 to FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,098 | 0 |
What was the value of Regeneron Pharmaceutical's biggest liability end of FY 2023? | Regeneron Pharmaceutical's biggest liability end of FY 2023 was Accrued Expenses and Other Liabilities that amounted to $2,357.9million. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,099 | 0 |
What was the value of Regeneron Pharmaceutical's biggest asset end of FY 2023? | Regeneron Pharmaceutical's biggest asset end of FY 2023 was Marketable Securities that amounted to $8,114.8 million. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,100 | 0 |
What was the current ratio of Regeneron Pharmaceutical end of FY 2023? | The current ratio of Regeneron Pharmaceutical end of FY 2023 was 5.69. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,101 | 0 |
What was Regeneron Pharmaceutical's quick ratio end of FY 2023? | Regeneron Pharmaceutical's quick ratio end of FY 2023 was 4.94. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,102 | 0 |
Did the long term debt of Regeneron Pharmaceutical increased from FY 2022 to FY 2023? | Yes, the long term debt of Regeneron Pharmaceutical increased slightly from FY $1,981.4 million in FY 2022 to $1,982.9 million in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,103 | 0 |
What was Regeneron Pharmaceutical's Debt to Equity ratio end of FY 2023? | Regenron Pharmaceutical's Debt to Equity ratio end of FY 2023 was 0.27. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,104 | 0 |
How has Regeneron Pharmaceutical's Debt to Equity ratio evolved from FY 2022 to FY 2023? | Regenron Pharmaceutical's Debt to Equity ratio lowered from 0.29 in FY 2022 to 0.27 in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,105 | 0 |
What was the Retained Earnings of Regeneron Pharmaceutical end of FY 2023? | Regenron Pharmaceutical's Retained Earnings end of FY 2023 was $27,260.3 million. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,106 | 0 |
What was the growth in Regeneron Pharmaceutical's Retained Earnings from FY 2022 to FY 2023? | Regenron Pharmaceutical's Retained Earnings grew by 16.9% from FY 2022 to FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED BALANCE SHEETS\n (In millions, except per share data)\n December 31,\n 2023 2022\n ASSETS\n Current assets:\n Cash and cash equivalents $ 2,730.0 $ 3,105.9\n Marketable securities 8,114.8 4,636.4\n Accounts receivable, net 5,667.3 5,328.7\n Inventories 2,580.5 2,401.9\n Prepaid expenses and other current assets 386.6 411.2\n Total current assets 19,479.2 15,884.1\n Marketable securities 5,396.5 6,591.8\n Property, plant, and equipment, net 4,146.4 3,763.0\n Intangible assets, net 1,038.6 915.5\n Deferred tax assets 2,575.4 1,723.7\n Other noncurrent assets 444.1 336.4\n Total assets $ 33,080.2 $ 29,214.5\n LIABILITIES AND STOCKHOLDERS' EQUITY\n Current liabilities:\n Accounts payable $ 606.6 $ 589.2\n Accrued expenses and other current liabilities 2,357.9 2,074.2\n Deferred revenue 458.9 477.9\n Total current liabilities 3,423.4 3,141.3\n Long-term debt 1,982.9 1,981.4\n Finance lease liabilities 720.0 720.0\n Deferred revenue 126.7 69.8\n Other noncurrent liabilities 854.1 638.0\n Total liabilities 7,107.1 6,550.5\n Commitments and contingencies\n Stockholders' equity:\n Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none — —\n Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding\n - 1.8 in 2023 and 2022 — —\n Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 133.1 in 2023 and 130.4\n in 2022 0.1 0.1\n Additional paid-in capital 11,354.0 9,949.3\n Retained earnings 27,260.3 23,306.7\n Accumulated other comprehensive loss (80.9) (238.8)\n Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022 (12,560.4) (10,353.3)\n Total stockholders' equity 25,973.1 22,664.0\n Total liabilities and stockholders' equity $ 33,080.2 $ 29,214.5"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,107 | 0 |
What was the Capital Expenditure of Regeneron Pharmaceutical in FY 2023? | The Capital Expenditure of Regeneron Pharmaceutical in FY 2023 was $718.6 million. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF CASH FLOWS\n (In millions)\n Year Ended December 31,\n 2023 2022 2021\n Cash flows from operating activities:\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Adjustments to reconcile net income to net cash provided by operating activities:\n Depreciation and amortization 421.0 341.4 286.2\n Stock-based compensation expense 885.0 725.0 601.7\n Losses (gains) on marketable and other securities, net 266.4 36.8 (387.0)\n Other non-cash items, net (0.1) 368.0 568.7\n Deferred income taxes (837.8) (746.4) (147.1)\n Acquired in-process research and development in connection with asset acquisition — 195.0 —\n Changes in assets and liabilities:\n (Increase) decrease in accounts receivable (338.8) 707.8 (1,927.4)\n Increase in inventories (271.7) (696.5) (494.3)\n Increase in prepaid expenses and other assets (120.1) (148.6) (240.7)\n Increase (decrease) in deferred revenue 37.9 32.4 (120.2)\n Increase (decrease) in accounts payable, accrued expenses, and other liabilities 598.6 (138.4) 866.1\n Total adjustments 640.4 676.5 (994.0)\n Net cash provided by operating activities 4,594.0 5,014.9 7,081.3\n Cash flows from investing activities:\n Purchases of marketable and other securities (11,646.0) (7,487.9) (7,048.1)\n Sales or maturities of marketable and other securities 9,442.2 5,550.5 2,215.3\n Capital expenditures (718.6) (590.1) (551.9)\n Payments for Libtayo intangible asset (207.8) (1,026.8) —\n Acquisitions, net of cash acquired (54.9) (230.3) —\n Net cash used in investing activities (3,185.1) (3,784.6) (5,384.7)\n Cash flows from financing activities:\n Proceeds from issuance of Common Stock 1,145.5 1,519.5 1,672.3\n Payments in connection with Common Stock tendered for employee tax obligations (700.6) (445.7) (1,032.7)\n Repurchases of Common Stock (2,235.0) (2,082.8) (1,645.4)\n Net cash used in financing activities (1,790.1) (1,009.0) (1,005.8)\n Effect of exchange rate changes on cash, cash equivalents, and restricted cash (0.4) — —\n Net (decrease) increase in cash, cash equivalents, and restricted cash (381.6) 221.3 690.8\n Cash, cash equivalents, and restricted cash at beginning of period 3,119.4 2,898.1 2,207.3\n Cash, cash equivalents, and restricted cash at end of period $ 2,737.8 $ 3,119.4 $ 2,898.1\n Supplemental disclosure of cash flow information\n Cash paid for interest (net of amounts capitalized) $ 73.1 $ 53.7 $ 55.8\n Cash paid for income taxes $ 870.3 $ 1,502.4 $ 1,218.4"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,108 | 0 |
How much did the Capital Expenditure grow for Regeneron Pharmaceutical from FY 2022 to FY 2023? | The Capital Expenditure of Regeneron Pharmaceutical grew by 21.8% from FY 2022 to FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF CASH FLOWS\n (In millions)\n Year Ended December 31,\n 2023 2022 2021\n Cash flows from operating activities:\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Adjustments to reconcile net income to net cash provided by operating activities:\n Depreciation and amortization 421.0 341.4 286.2\n Stock-based compensation expense 885.0 725.0 601.7\n Losses (gains) on marketable and other securities, net 266.4 36.8 (387.0)\n Other non-cash items, net (0.1) 368.0 568.7\n Deferred income taxes (837.8) (746.4) (147.1)\n Acquired in-process research and development in connection with asset acquisition — 195.0 —\n Changes in assets and liabilities:\n (Increase) decrease in accounts receivable (338.8) 707.8 (1,927.4)\n Increase in inventories (271.7) (696.5) (494.3)\n Increase in prepaid expenses and other assets (120.1) (148.6) (240.7)\n Increase (decrease) in deferred revenue 37.9 32.4 (120.2)\n Increase (decrease) in accounts payable, accrued expenses, and other liabilities 598.6 (138.4) 866.1\n Total adjustments 640.4 676.5 (994.0)\n Net cash provided by operating activities 4,594.0 5,014.9 7,081.3\n Cash flows from investing activities:\n Purchases of marketable and other securities (11,646.0) (7,487.9) (7,048.1)\n Sales or maturities of marketable and other securities 9,442.2 5,550.5 2,215.3\n Capital expenditures (718.6) (590.1) (551.9)\n Payments for Libtayo intangible asset (207.8) (1,026.8) —\n Acquisitions, net of cash acquired (54.9) (230.3) —\n Net cash used in investing activities (3,185.1) (3,784.6) (5,384.7)\n Cash flows from financing activities:\n Proceeds from issuance of Common Stock 1,145.5 1,519.5 1,672.3\n Payments in connection with Common Stock tendered for employee tax obligations (700.6) (445.7) (1,032.7)\n Repurchases of Common Stock (2,235.0) (2,082.8) (1,645.4)\n Net cash used in financing activities (1,790.1) (1,009.0) (1,005.8)\n Effect of exchange rate changes on cash, cash equivalents, and restricted cash (0.4) — —\n Net (decrease) increase in cash, cash equivalents, and restricted cash (381.6) 221.3 690.8\n Cash, cash equivalents, and restricted cash at beginning of period 3,119.4 2,898.1 2,207.3\n Cash, cash equivalents, and restricted cash at end of period $ 2,737.8 $ 3,119.4 $ 2,898.1\n Supplemental disclosure of cash flow information\n Cash paid for interest (net of amounts capitalized) $ 73.1 $ 53.7 $ 55.8\n Cash paid for income taxes $ 870.3 $ 1,502.4 $ 1,218.4"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,109 | 0 |
Did Regeneron Pharmaceutical repurchase its Common Stock in FY 2023? | Yes, Regeneron Pharmaceutical bought back its Common shares worth $2,235 million in FY 2023. | [
"REGENERON PHARMACEUTICALS, INC.\n CONSOLIDATED STATEMENTS OF CASH FLOWS\n (In millions)\n Year Ended December 31,\n 2023 2022 2021\n Cash flows from operating activities:\n Net income $ 3,953.6 $ 4,338.4 $ 8,075.3\n Adjustments to reconcile net income to net cash provided by operating activities:\n Depreciation and amortization 421.0 341.4 286.2\n Stock-based compensation expense 885.0 725.0 601.7\n Losses (gains) on marketable and other securities, net 266.4 36.8 (387.0)\n Other non-cash items, net (0.1) 368.0 568.7\n Deferred income taxes (837.8) (746.4) (147.1)\n Acquired in-process research and development in connection with asset acquisition — 195.0 —\n Changes in assets and liabilities:\n (Increase) decrease in accounts receivable (338.8) 707.8 (1,927.4)\n Increase in inventories (271.7) (696.5) (494.3)\n Increase in prepaid expenses and other assets (120.1) (148.6) (240.7)\n Increase (decrease) in deferred revenue 37.9 32.4 (120.2)\n Increase (decrease) in accounts payable, accrued expenses, and other liabilities 598.6 (138.4) 866.1\n Total adjustments 640.4 676.5 (994.0)\n Net cash provided by operating activities 4,594.0 5,014.9 7,081.3\n Cash flows from investing activities:\n Purchases of marketable and other securities (11,646.0) (7,487.9) (7,048.1)\n Sales or maturities of marketable and other securities 9,442.2 5,550.5 2,215.3\n Capital expenditures (718.6) (590.1) (551.9)\n Payments for Libtayo intangible asset (207.8) (1,026.8) —\n Acquisitions, net of cash acquired (54.9) (230.3) —\n Net cash used in investing activities (3,185.1) (3,784.6) (5,384.7)\n Cash flows from financing activities:\n Proceeds from issuance of Common Stock 1,145.5 1,519.5 1,672.3\n Payments in connection with Common Stock tendered for employee tax obligations (700.6) (445.7) (1,032.7)\n Repurchases of Common Stock (2,235.0) (2,082.8) (1,645.4)\n Net cash used in financing activities (1,790.1) (1,009.0) (1,005.8)\n Effect of exchange rate changes on cash, cash equivalents, and restricted cash (0.4) — —\n Net (decrease) increase in cash, cash equivalents, and restricted cash (381.6) 221.3 690.8\n Cash, cash equivalents, and restricted cash at beginning of period 3,119.4 2,898.1 2,207.3\n Cash, cash equivalents, and restricted cash at end of period $ 2,737.8 $ 3,119.4 $ 2,898.1\n Supplemental disclosure of cash flow information\n Cash paid for interest (net of amounts capitalized) $ 73.1 $ 53.7 $ 55.8\n Cash paid for income taxes $ 870.3 $ 1,502.4 $ 1,218.4"
] | REGENERON PHARMACEUTICALS, INC. | REGN | 2,024 | 2024-02-05 | 872,589 | Healthcare | https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm | 2,110 | 0 |
What is the total net revenue of Intel Corp. for the year ending December 30th, 2023? | The net revenue for FY2023 was $54,228 million. | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,161 | 0 |
What is the YoY growth of Intel Corp's total net reveue between FY2022 and FY2023? | Intel Corp experienced a negative growth of 14% from FY 2022 to FY 2023. | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,162 | 0 |
What was Intel Corp's Cost of Sales for FY 2023? | Intel Corp's Cost of Sales amounted to $32,517 million. | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,163 | 0 |
What was Intel Corp's Gross Margin for FY 2021? | Intel Corp's Gross Margin amounted to $43,815 million. | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,164 | 0 |
How much were the Marketing, general, and administrative expenses for Intel Corp in FY 2023? | Marketing, general, and administrative expenses totalled $5,634 million. | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,165 | 0 |
Of all the operating expenses, which expense had the major share in Intel Corp's operating expenses in FY2023? | Research and development is the major part of operating expenses in FY2023. It accounts for 74.23% of the total operating expenses. | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,166 | 0 |
How much change was observed in Intel Corp's gross margin (in percentage terms) from FY 2022 to FY 2023? | Intel Corp's gross margin fell by 19.19% from FY2022 to $21,711 million in FY2023 | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,167 | 0 |
What is the percentage increase in the cost of sales from FY2021 to FY2022 for Intel Corp? | Intel Corp's cost of sales increased by 2.78% in FY2022 | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,168 | 0 |
What is Intel Corp's basic and diluted EPS for the FY2023? | Intel Corp's basic and diluted EPS for FY2023 is $0.40 | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,169 | 0 |
What is the YoY growth between FY22 and FY23 on the basic EPS of Intel Corp? | The basic EPS for Intel Corp decreased by 79.49% in FY2023. It was $1.95 in FY2022 and fell to $0.40 in FY2023 | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,170 | 0 |
Using the basic EPS of FY2023, what is the number of common shares of Intel Corp? | Common shares outstanding of Intel Corp in FY2023 were 4190 million. | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,171 | 0 |
What is the quick ratio of Intel Corp for FY2023? | Intel Corp's quick ratio is 1.146 | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,172 | 0 |
By how much has the quick ratio increased/decreased from FY2022? | The quick ratio for Intel Corp decreased by 0.92%, from 1.156 to 1.146 in FY2023. | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,173 | 0 |
What was the current ratio of Intel Corp for FY2022? | Intel Corp's current ratio in FY2022 equates to 1.542 | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,174 | 0 |
What was the Day Sales Outstanding for Intel Corp in FY2023? | DSO for Intel Corp in FY2023 are 25.35 days | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103",
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,175 | 0 |
Has the DSO increased / decreased from FY2022? If so, by how much? | DSO for Intel Corp was 23.92 days in FY2022. It has improved by 1.03 days in the following year. | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103",
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,176 | 0 |
What was the Days Payables Outstanding for Intel Corp in FY2023? | Intel Corp's DPO for FY2023 is 96.29 days | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103",
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,177 | 0 |
What was the Days Inventory Outstanding for Intel Corp in FY2023? | Days Inventory Outstanding for Intel Corp in FY2023 were 124.9 days | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103",
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,178 | 0 |
What would be the working capital cycle for Intel Corp for FY2023? | Intel Corp's Working Capital Cycle for FY2023 is 51.51 days | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103",
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,179 | 0 |
What was the Debt to Equity ratio of Intel Corp in FY2023? | Intel's Debt to Equity ratio for FY2023 was 44.49% | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,180 | 0 |
What was the Asset turnover ratio of Intel Corp in FY2023? | The Asset turnover for Intel Corp was 28.31% in FY2023 | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103",
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,181 | 0 |
What was the Return on Equity ratio of Intel Corp in FY2023? | Intel Corp's ROE in FY2023 was 1.60% | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103",
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,182 | 0 |
What was the Interest Cover ratio of Intel Corp in FY2022? | Intel Corp's Interest Cover ratio was 2 times in FY2022. | [
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,183 | 0 |
What was the capital intensity ratio of Intel Corp in FY2023? | Intel Corp's capital intensity ratio for FY2023 is 3.44 | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103",
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,184 | 0 |
How has Intel's capital intensity ratio evolved from FY2022? | The capital intensity ratio was 2.89 in FY2022. It has increased by 0.64 from FY2022 to 3.53 | [
"Consolidated Balance Sheets (In Millions, Except Par Value) Dec 30, 2023 Dec 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,079 $ 11,144 Short-term investments 17,955 17,194 Accounts receivable, net 3,402 4,133 Inventories 11,127 13,224 Other current assets 3,706 4,712 Total current assets 43,269 50,407 Property, plant, and equipment, net 96,647 80,860 Equity investments 5,829 5,912 Goodwill 27,591 27,591 Identified intangible assets, net 4,589 6,018 Other long-term assets 13,647 11,315 Total assets $ 191,572 $ 182,103 Liabilities and stockholders' equity Current liabilities: Short-term debt $ 2,288 $ 4,367 Accounts payable 8,578 9,595 Accrued compensation and benefits 3,655 4,084 Income taxes payable 1,107 2,251 Other accrued liabilities 12,425 11,858 Total current liabilities 28,053 32,155 Debt 46,978 37,684 Other long-term liabilities 6,576 8,978 Commitments and Contingencies (Note 19) Stockholders' equity: Preferred stock, $0.001 par value, 50 shares authorized; none issued — — Common stock, $0.001 par value, 10,000 shares authorized; 4,228 shares issued and outstanding (4,137 issued and outstanding in 2022) and capital in excess of par value 36,649 31,580 Accumulated other comprehensive income (loss) (215) (562) Retained earnings 69,156 70,405 Total Intel stockholders' equity 105,590 101,423 Non-controlling interests 4,375 1,863 Total stockholders' equity 109,965 103,286 Total liabilities and stockholders' equity $ 191,572 $ 182,103",
"Consolidated Statements of Income Years Ended (In Millions, Except Per Share Amounts) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue $ 54,228 $ 63,054 $ 79,024 Cost of sales 32,517 36,188 35,209 Gross margin 21,711 26,866 43,815 Research and development 16,046 17,528 15,190 Marketing, general, and administrative 5,634 7,002 6,543 Restructuring and other charges (62) 2 2,626 Operating expenses 21,618 24,532 24,359 Operating income 93 2,334 19,456 Gains (losses) on equity investments, net 40 4,268 2,729 Interest and other, net 629 1,166 (482) Income before taxes 762 7,768 21,703 Provision for (benefit from) taxes (913) (249) 1,835 Net income 1,675 8,017 19,868 Less: Net income (loss) attributable to non-controlling interests (14) 3 — Net income attributable to Intel $ 1,689 $ 8,014 $ 19,868 Earnings per share attributable to Intel—basic $ 0.40 $ 1.95 $ 4.89 Earnings per share attributable to Intel—diluted $ 0.40 $ 1.94 $ 4.86 Weighted average shares of common stock outstanding: Basic 4,190 4,108 4,059 Diluted 4,212 4,123 4,090"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,185 | 0 |
What was the split of notebook and desktop revenue for Intel Corp from the total net revenue in FY2023? | Net Revenue for Desktops in FY 2023 was $10,166 million and for Notebooks was $16,990 million. | [
"Net revenue and operating income (loss) for each period were as follows: Years Ended (In Millions) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue: Client Computing Desktop $ 10,166 $ 10,661 $ 12,437 Notebook 16,990 18,781 25,443 Other 2,102 2,331 3,201 29,258 31,773 41,081 Data Center and AI $ 15,521 $ 19,445 $ 22,774 Network and Edge 5,774 8,409 7,665 Mobileye 2,079 1,869 1,386 Intel Foundry Services 952 469 347 All other 644 1,089 5,771 Total net revenue $ 54,228 $ 63,054 $ 79,024 Operating income (loss): Client Computing $ 6,520 $ 5,569 $ 15,523 Data Center and AI (530) 1,300 7,376 Network and Edge (482) 1,033 1,935 Mobileye 664 690 554 Intel Foundry Services (482) (281) 76 All other (5,597) (5,977) (6,008) Total operating income (loss) $ 93 $ 2,334 $ 19,456"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,186 | 0 |
Other than client computing, which component had the highest share of the total net revenue in FY2023? | Data Center and AI segment had the highest share with a net revenue of $15,521 million. | [
"Net revenue and operating income (loss) for each period were as follows: Years Ended (In Millions) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue: Client Computing Desktop $ 10,166 $ 10,661 $ 12,437 Notebook 16,990 18,781 25,443 Other 2,102 2,331 3,201 29,258 31,773 41,081 Data Center and AI $ 15,521 $ 19,445 $ 22,774 Network and Edge 5,774 8,409 7,665 Mobileye 2,079 1,869 1,386 Intel Foundry Services 952 469 347 All other 644 1,089 5,771 Total net revenue $ 54,228 $ 63,054 $ 79,024 Operating income (loss): Client Computing $ 6,520 $ 5,569 $ 15,523 Data Center and AI (530) 1,300 7,376 Network and Edge (482) 1,033 1,935 Mobileye 664 690 554 Intel Foundry Services (482) (281) 76 All other (5,597) (5,977) (6,008) Total operating income (loss) $ 93 $ 2,334 $ 19,456"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,187 | 0 |
What was the operating income of Intel Corp's Mobileye segment in FY2023? | The operating income for Mobileye was $664 million | [
"Net revenue and operating income (loss) for each period were as follows: Years Ended (In Millions) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue: Client Computing Desktop $ 10,166 $ 10,661 $ 12,437 Notebook 16,990 18,781 25,443 Other 2,102 2,331 3,201 29,258 31,773 41,081 Data Center and AI $ 15,521 $ 19,445 $ 22,774 Network and Edge 5,774 8,409 7,665 Mobileye 2,079 1,869 1,386 Intel Foundry Services 952 469 347 All other 644 1,089 5,771 Total net revenue $ 54,228 $ 63,054 $ 79,024 Operating income (loss): Client Computing $ 6,520 $ 5,569 $ 15,523 Data Center and AI (530) 1,300 7,376 Network and Edge (482) 1,033 1,935 Mobileye 664 690 554 Intel Foundry Services (482) (281) 76 All other (5,597) (5,977) (6,008) Total operating income (loss) $ 93 $ 2,334 $ 19,456"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,188 | 0 |
What was the percentage increase/decrease in Mobileye's operating income for Intel Corp from FY2022? | Mobileye's operating income declined by 3.77% from FY2022 | [
"Net revenue and operating income (loss) for each period were as follows: Years Ended (In Millions) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue: Client Computing Desktop $ 10,166 $ 10,661 $ 12,437 Notebook 16,990 18,781 25,443 Other 2,102 2,331 3,201 29,258 31,773 41,081 Data Center and AI $ 15,521 $ 19,445 $ 22,774 Network and Edge 5,774 8,409 7,665 Mobileye 2,079 1,869 1,386 Intel Foundry Services 952 469 347 All other 644 1,089 5,771 Total net revenue $ 54,228 $ 63,054 $ 79,024 Operating income (loss): Client Computing $ 6,520 $ 5,569 $ 15,523 Data Center and AI (530) 1,300 7,376 Network and Edge (482) 1,033 1,935 Mobileye 664 690 554 Intel Foundry Services (482) (281) 76 All other (5,597) (5,977) (6,008) Total operating income (loss) $ 93 $ 2,334 $ 19,456"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,189 | 0 |
What was the Cost of revenue for Intel Corp's client computing segment in FY2023? | Client Computing's cost of revenue amounted to $22,738 in FY2023 | [
"Net revenue and operating income (loss) for each period were as follows: Years Ended (In Millions) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue: Client Computing Desktop $ 10,166 $ 10,661 $ 12,437 Notebook 16,990 18,781 25,443 Other 2,102 2,331 3,201 29,258 31,773 41,081 Data Center and AI $ 15,521 $ 19,445 $ 22,774 Network and Edge 5,774 8,409 7,665 Mobileye 2,079 1,869 1,386 Intel Foundry Services 952 469 347 All other 644 1,089 5,771 Total net revenue $ 54,228 $ 63,054 $ 79,024 Operating income (loss): Client Computing $ 6,520 $ 5,569 $ 15,523 Data Center and AI (530) 1,300 7,376 Network and Edge (482) 1,033 1,935 Mobileye 664 690 554 Intel Foundry Services (482) (281) 76 All other (5,597) (5,977) (6,008) Total operating income (loss) $ 93 $ 2,334 $ 19,456"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,190 | 0 |
Is there an improvement or decline in Intel Corp.'s total operating income for FY2023 compared to the FY2022? | Intel Corp's operating income fell by 96.02% in FY2023. It decreased from $2,334 million to $93 million | [
"Net revenue and operating income (loss) for each period were as follows: Years Ended (In Millions) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue: Client Computing Desktop $ 10,166 $ 10,661 $ 12,437 Notebook 16,990 18,781 25,443 Other 2,102 2,331 3,201 29,258 31,773 41,081 Data Center and AI $ 15,521 $ 19,445 $ 22,774 Network and Edge 5,774 8,409 7,665 Mobileye 2,079 1,869 1,386 Intel Foundry Services 952 469 347 All other 644 1,089 5,771 Total net revenue $ 54,228 $ 63,054 $ 79,024 Operating income (loss): Client Computing $ 6,520 $ 5,569 $ 15,523 Data Center and AI (530) 1,300 7,376 Network and Edge (482) 1,033 1,935 Mobileye 664 690 554 Intel Foundry Services (482) (281) 76 All other (5,597) (5,977) (6,008) Total operating income (loss) $ 93 $ 2,334 $ 19,456"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,191 | 0 |
What was the Compound Annual Growth Rate (CAGR) of revenue for Intel Corp over the past 3 years? | Intel Corp's net revenue experienced a CAGR of -11.80% in the past 3 years. | [
"Net revenue and operating income (loss) for each period were as follows: Years Ended (In Millions) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Net revenue: Client Computing Desktop $ 10,166 $ 10,661 $ 12,437 Notebook 16,990 18,781 25,443 Other 2,102 2,331 3,201 29,258 31,773 41,081 Data Center and AI $ 15,521 $ 19,445 $ 22,774 Network and Edge 5,774 8,409 7,665 Mobileye 2,079 1,869 1,386 Intel Foundry Services 952 469 347 All other 644 1,089 5,771 Total net revenue $ 54,228 $ 63,054 $ 79,024 Operating income (loss): Client Computing $ 6,520 $ 5,569 $ 15,523 Data Center and AI (530) 1,300 7,376 Network and Edge (482) 1,033 1,935 Mobileye 664 690 554 Intel Foundry Services (482) (281) 76 All other (5,597) (5,977) (6,008) Total operating income (loss) $ 93 $ 2,334 $ 19,456"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,192 | 0 |
How much dividend was paid to common shareholders in FY2023 by Intel Corp? | Total dividend paid in FY2023 to common shareholders amounted to $3,088 million. | [
"Consolidated Statements of Cash Flows Years Ended (In Millions) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Cash and cash equivalents, beginning of period $ 11,144 $ 4,827 $ 5,865 Cash flows provided by (used for) operating activities: Net income 1,675 8,017 19,868 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 7,847 11,128 9,953 Share-based compensation 3,229 3,128 2,036 Restructuring and other charges (424) 1,074 2,626 Amortization of intangibles 1,755 1,907 1,839 (Gains) losses on equity investments, net (42) (4,254) (1,458) (Gains) losses on divestitures — (1,059) — Changes in assets and liabilities: Accounts receivable 731 5,327 (2,674) Inventories 2,097 (2,436) (2,339) Accounts payable (801) (29) 1,190 Accrued compensation and benefits (614) (1,533) 515 Prepaid customer supply agreements — (24) (1,583) Income taxes (3,531) (4,535) (441) Other assets and liabilities (451) (1,278) (76) Total adjustments 9,796 7,416 9,588 Net cash provided by operating activities 11,471 15,433 29,456 Cash flows provided by (used for) investing activities: Additions to property, plant, and equipment (25,750) (24,844) (18,733) Additions to held for sale NAND property, plant, and equipment — (206) (1,596) Proceeds from capital-related government incentives 1,011 246 166 Purchase of short-term investments (44,414) (43,647) (40,554) Maturities and sales of short-term investments 44,077 48,730 35,299 Purchases of equity investments (399) (510) (613) Sales of equity investments 472 4,961 581 Proceeds from divestitures — 6,579 — Other investing 962 (1,540) 1,167 Net cash used for investing activities (24,041) (10,231) (24,283) Cash flows provided by (used for) financing activities: Issuance of commercial paper, net of issuance costs — 3,945 — Repayment of commercial paper (3,944) — — Payments on finance leases (96) (345) — Partner contributions 1,511 874 — Proceeds from sales of subsidiary shares 2,959 1,032 — Issuance of long-term debt, net of issuance costs 11,391 6,548 4,974 Repayment of debt (423) (4,984) (2,500) Proceeds from sales of common stock through employee equity incentive plans 1,042 977 1,020 Repurchase of common stock — — (2,415) Payment of dividends to stockholders (3,088) (5,997) (5,644) Other financing (847) (935) (1,646) Net cash provided by (used for) financing activities 8,505 1,115 (6,211) Net increase (decrease) in cash and cash equivalents (4,065) 6,317 (1,038) Cash and cash equivalents, end of period $ 7,079 $ 11,144 $ 4,827 Supplemental disclosures: Acquisition of property, plant, and equipment included in accounts payable and accrued liabilities $ 4,804 $ 5,431 $ 1,619 Cash paid during the year for: Interest, net of capitalized interest $ 613 $ 459 $ 545 Income taxes, net of refunds $ 2,621 $ 4,282 $ 2,263"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,193 | 0 |
By what amount has the total dividend paid by Intel Corp increased/decreased from FY2022? | Intel Corp's total dividend payout decreased by 48.5% in FY2023 to $3,088 million | [
"Consolidated Statements of Cash Flows Years Ended (In Millions) Dec 30, 2023 Dec 31, 2022 Dec 25, 2021 Cash and cash equivalents, beginning of period $ 11,144 $ 4,827 $ 5,865 Cash flows provided by (used for) operating activities: Net income 1,675 8,017 19,868 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 7,847 11,128 9,953 Share-based compensation 3,229 3,128 2,036 Restructuring and other charges (424) 1,074 2,626 Amortization of intangibles 1,755 1,907 1,839 (Gains) losses on equity investments, net (42) (4,254) (1,458) (Gains) losses on divestitures — (1,059) — Changes in assets and liabilities: Accounts receivable 731 5,327 (2,674) Inventories 2,097 (2,436) (2,339) Accounts payable (801) (29) 1,190 Accrued compensation and benefits (614) (1,533) 515 Prepaid customer supply agreements — (24) (1,583) Income taxes (3,531) (4,535) (441) Other assets and liabilities (451) (1,278) (76) Total adjustments 9,796 7,416 9,588 Net cash provided by operating activities 11,471 15,433 29,456 Cash flows provided by (used for) investing activities: Additions to property, plant, and equipment (25,750) (24,844) (18,733) Additions to held for sale NAND property, plant, and equipment — (206) (1,596) Proceeds from capital-related government incentives 1,011 246 166 Purchase of short-term investments (44,414) (43,647) (40,554) Maturities and sales of short-term investments 44,077 48,730 35,299 Purchases of equity investments (399) (510) (613) Sales of equity investments 472 4,961 581 Proceeds from divestitures — 6,579 — Other investing 962 (1,540) 1,167 Net cash used for investing activities (24,041) (10,231) (24,283) Cash flows provided by (used for) financing activities: Issuance of commercial paper, net of issuance costs — 3,945 — Repayment of commercial paper (3,944) — — Payments on finance leases (96) (345) — Partner contributions 1,511 874 — Proceeds from sales of subsidiary shares 2,959 1,032 — Issuance of long-term debt, net of issuance costs 11,391 6,548 4,974 Repayment of debt (423) (4,984) (2,500) Proceeds from sales of common stock through employee equity incentive plans 1,042 977 1,020 Repurchase of common stock — — (2,415) Payment of dividends to stockholders (3,088) (5,997) (5,644) Other financing (847) (935) (1,646) Net cash provided by (used for) financing activities 8,505 1,115 (6,211) Net increase (decrease) in cash and cash equivalents (4,065) 6,317 (1,038) Cash and cash equivalents, end of period $ 7,079 $ 11,144 $ 4,827 Supplemental disclosures: Acquisition of property, plant, and equipment included in accounts payable and accrued liabilities $ 4,804 $ 5,431 $ 1,619 Cash paid during the year for: Interest, net of capitalized interest $ 613 $ 459 $ 545 Income taxes, net of refunds $ 2,621 $ 4,282 $ 2,263"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,194 | 0 |
What value of Intel Corp's total inventory for FY2023 is finished goods? | $3,758 million of total inventories were part of finished goods in FY2023. | [
"Inventories (In Millions) Dec 30, 2023 Dec 31, 2022 Raw materials $ 1,166 $ 1,517 Work in process 6,203 7,565 Finished goods 3,758 4,142 Total inventories $ 11,127 $ 13,224"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,195 | 0 |
What was the valuation of Intel Corp's inventory that was part of Raw Materials in FY2022? | Inventory that was Raw Materials accounted for $1,517 million in FY2021 | [
"Inventories (In Millions) Dec 30, 2023 Dec 31, 2022 Raw materials $ 1,166 $ 1,517 Work in process 6,203 7,565 Finished goods 3,758 4,142 Total inventories $ 11,127 $ 13,224"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,196 | 0 |
What was the percentage increase/decrease in Intel Corp's work in process inventory from FY2022 to FY2023? | Intel Corp's work in process inventory's value decreased by 18% from FY2022 to $6,203 million. | [
"Inventories (In Millions) Dec 30, 2023 Dec 31, 2022 Raw materials $ 1,166 $ 1,517 Work in process 6,203 7,565 Finished goods 3,758 4,142 Total inventories $ 11,127 $ 13,224"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,197 | 0 |
How much were Intel Corp's net total identified intangible assets for FY2023? | Intel's net total identified intangible assets for FY2023 were $4,589 million. | [
"Note 12 : Identified Intangible Assets December 30, 2023 December 31, 2022 (In Millions) Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Developed technology $ 10,520 $ (7,996) $ 2,524 $ 10,964 $ (7,216) $ 3,748 Customer relationships and brands 1,986 (1,286) 700 1,986 (1,114) 872 Licensed technology and patents 3,088 (1,728) 1,360 3,219 (1,821) 1,398 Other non-amortizing intangibles 5 — 5 — — — Total identified intangible assets $ 15,599 $ (11,010) $ 4,589 $ 16,169 $ (10,151) $ 6,018"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,198 | 0 |
What is the gross amount of "developed technology" under the identified intangible assets for Intel Corp in FY2023? | The gross value for developed technology is $10,520 million in FY2023 | [
"Note 12 : Identified Intangible Assets December 30, 2023 December 31, 2022 (In Millions) Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Developed technology $ 10,520 $ (7,996) $ 2,524 $ 10,964 $ (7,216) $ 3,748 Customer relationships and brands 1,986 (1,286) 700 1,986 (1,114) 872 Licensed technology and patents 3,088 (1,728) 1,360 3,219 (1,821) 1,398 Other non-amortizing intangibles 5 — 5 — — — Total identified intangible assets $ 15,599 $ (11,010) $ 4,589 $ 16,169 $ (10,151) $ 6,018"
] | INTEL CORP | INTC | 2,024 | 2024-01-25 | 50,863 | Information Technology | https://www.sec.gov/Archives/edgar/data/50863/000005086324000010/intc-20231230.htm | 2,199 | 0 |